Other Clinical Trial - A Safety & Tolerability Study of INCB053914 in

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04572763` - Copanlisib Plus Venetoclax in R/R DLBCL	Phase 1/Phase 2
Recruiting	`NCT06047197` - Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma	Phase 1
Active, not recruiting	`NCT03136497` - A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 1
Completed	`NCT03287817` - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05890352` - Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment	Phase 2
Active, not recruiting	`NCT01955499` - Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1
Active, not recruiting	`NCT03321643` - Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma	Phase 1
Recruiting	`NCT05052528` - Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Phase 1
Recruiting	`NCT04384484` - Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Phase 3
Active, not recruiting	`NCT03259503` - Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	Phase 1
Completed	`NCT02219737` - Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Phase 1
Active, not recruiting	`NCT03583424` - Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT02874404` - TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Phase 2
Recruiting	`NCT04007029` - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Phase 1
Withdrawn	`NCT03579927` - CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	Phase 1/Phase 2
Terminated	`NCT03272633` - Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	Early Phase 1
Completed	`NCT03309878` - Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma	Phase 1/Phase 2
Completed	`NCT02405078` - Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Early Phase 1
Completed	`NCT03019640` - Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT03892044` - Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma	Phase 1

NCT number	NCT03688152
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Completed
Phase	Phase 1
Start date	December 3, 2018
Completion date	September 1, 2020

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms